Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon Mar 30, 2022 5:24pm
152 Views
Post# 34560675

Samira purchased 20,000 shares & 425,000 options expire

Samira purchased 20,000 shares & 425,000 options expire
Filed 2022-03-30 16:57
 
Tx date 2022-03-25
$GUD
Knight Therapeutics Inc.
Goodman, Jonathan Ross
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Options
52 - Expiration of options
$-2,537,500
-290,000 vol
$8.75 each
2,179,548  
Filed 2022-03-30 16:52
 
Tx date 2022-03-25
$GUD
Knight Therapeutics Inc.
Khouri, Amal
5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options
$-1,181,250
-135,000 vol
$8.75 each
424,758  
Filed 2022-03-30 16:06
 
Tx date 2022-03-30
$GUD
Knight Therapeutics Inc.
Sakhia, Samira
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$103,600
+20,000 vol
$5.18 each
117,429

<< Previous
Bullboard Posts
Next >>